Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226257711> ?p ?o ?g. }
- W4226257711 abstract "Background Targeted therapies directed at specific driver oncogenes have improved outcomes for individuals with advanced non‐small cell lung cancer (NSCLC). Approximately 5% of lung adenocarcinomas, the most common histologic subtype of NSCLC, harbour rearrangements in the anaplastic lymphoma kinase (ALK) gene leading to constitutive activity of the ALK kinase. Crizotinib was the first tyrosine kinase inhibitor (TKI) demonstrated to be effective in advanced NSCLC. Next‐generation ALK TKIs have since been developed including ceritinib, alectinib, brigatinib, ensartinib, and lorlatinib, and have been compared with crizotinib or chemotherapy in randomised controlled trials (RCTs). These ALK‐targeted therapies are currently used in clinical practice and are endorsed in multiple clinical oncology guidelines. Objectives To evaluate the safety and efficacy of ALK inhibitors given as monotherapy to treat advanced ALK‐rearranged NSCLC. Search methods We conducted electronic searches in the Cochrane Lung Cancer Group Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We also searched conference proceedings from the American Society for Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, as well as the reference lists of retrieved articles. All searches were conducted from 2007 until 7 January 2021. Selection criteria We included RCTs comparing ALK inhibitors with cytotoxic chemotherapy or another ALK inhibitor in individuals with incurable locally advanced or metastatic pathologically confirmed ALK‐rearranged NSCLC. Data collection and analysis Two review authors independently assessed studies for eligibility, extracted study characteristics and outcome data, and assessed risk of bias using the Cochrane risk of bias tool for each included study. We assessed the certainty of evidence using GRADE. Primary outcomes were progression‐free survival (PFS) and adverse events (AE); secondary outcomes were overall survival (OS), OS at one year, overall response rate (ORR) by RECIST (Response Evaluation Criteria in Solid Tumours) criteria, and health‐related quality of life (HRQoL). We performed a meta‐analysis for all outcomes, where appropriate, using the fixed‐effect model. We reported hazard ratios (HR) for PFS, OS, and a composite HRQoL of life outcome (time to deterioration), and risk ratios (RR) for AE, ORR, and one‐year OS. We presented 95% confidence intervals (95% CIs) and used the I² statistic to investigate heterogeneity. We planned comparisons of 'ALK inhibitor versus chemotherapy' and 'next‐generation ALK inhibitor versus crizotinib’ with subgroup analysis by type of ALK inhibitor, line of treatment, and baseline central nervous system involvement. Main results Eleven studies (2874 participants) met our inclusion criteria: six studies compared an ALK inhibitor (crizotinib, ceritinib, and alectinib) to chemotherapy, and five studies compared a next‐generation ALK inhibitor (alectinib, brigatinib, and lorlatinib) to crizotinib. We assessed the evidence for most outcomes as of moderate to high certainty. Most studies were at low risk for selection, attrition, and reporting bias; however, no RCTs were blinded, resulting in a high risk of performance and detection bias for outcomes reliant on subjective measurement. ALK inhibitor versus chemotherapy Treatment with ALK inhibitors resulted in a large increase in PFS compared to chemotherapy (HR 0.45, 95% CI 0.40 to 0.52, 6 RCTs, 1611 participants, high‐certainty evidence). This was found regardless of line of treatment. ALK inhibitors may result in no difference in overall AE rate when compared to chemotherapy (RR 1.01, 95% CI 1.00 to 1.03, 5 RCTs, 1404 participants, low‐certainty evidence). ALK inhibitors slightly improved OS (HR 0.84, 95% CI 0.72 to 0.97, 6 RCTs, 1611 participants, high‐certainty evidence), despite most included studies having a significant number of participants crossing over from chemotherapy to receive an ALK inhibitor after the study period. ALK inhibitors likely increase ORR (RR 2.43, 95% CI 2.16 to 2.75, 6 RCTs, 1611 participants, moderate‐certainty evidence) including in measurable baseline brain metastases (RR 4.88, 95% CI 2.18 to 10.95, 3 RCTs, 108 participants) when compared to chemotherapy. ALK inhibitors result in a large increase in the HRQoL measure, time to deterioration (HR 0.52, 95% CI 0.44 to 0.60, 5 RCTs, 1504 participants, high‐certainty evidence) when compared to chemotherapy. Next‐generation ALK inhibitor versus crizotinib Next‐generation ALK inhibitors resulted in a large increase in PFS (HR 0.39, 95% CI 0.33 to 0.46, 5 RCTs, 1263 participants, high‐certainty evidence), particularly in participants with baseline brain metastases. Next‐generation ALK inhibitors likely result in no difference in overall AE (RR 1.00, 95% CI 0.98 to 1.01, 5 RCTs, 1263 participants, moderate‐certainty evidence) when compared to crizotinib. Next‐generation ALK inhibitors likely increase OS (HR 0.71, 95% CI 0.56 to 0.90, 5 RCTs, 1263 participants, moderate‐certainty evidence) and slightly increase ORR (RR 1.18, 95% CI 1.10 to 1.25, 5 RCTs, 1229 participants, moderate‐certainty evidence) including a response in measurable brain metastases (RR 2.45, 95% CI 1.7 to 3.54, 4 RCTs, 138 participants) when compared to crizotinib. Studies comparing ALK inhibitors were conducted exclusively or partly in the first‐line setting. Authors' conclusions Next‐generation ALK inhibitors including alectinib, brigatinib, and lorlatinib are the preferred first systemic treatment for individuals with advanced ALK‐rearranged NSCLC. Further trials are ongoing including investigation of first‐line ensartinib. Next‐generation inhibitors have not been compared to each other, and it is unknown which should be used first and what subsequent treatment sequence is optimal." @default.
- W4226257711 created "2022-05-05" @default.
- W4226257711 creator A5016265614 @default.
- W4226257711 creator A5019354472 @default.
- W4226257711 creator A5023616126 @default.
- W4226257711 creator A5031092629 @default.
- W4226257711 creator A5036305114 @default.
- W4226257711 creator A5045959942 @default.
- W4226257711 creator A5072564095 @default.
- W4226257711 date "2022-01-07" @default.
- W4226257711 modified "2023-10-15" @default.
- W4226257711 title "Targeted therapy for advanced anaplastic lymphoma kinase (<i>ALK</i> )-rearranged non-small cell lung cancer" @default.
- W4226257711 cites W1224937636 @default.
- W4226257711 cites W1960242027 @default.
- W4226257711 cites W1992624894 @default.
- W4226257711 cites W1999218614 @default.
- W4226257711 cites W2009671306 @default.
- W4226257711 cites W2019607817 @default.
- W4226257711 cites W2036099482 @default.
- W4226257711 cites W2037139573 @default.
- W4226257711 cites W2040317578 @default.
- W4226257711 cites W2050249255 @default.
- W4226257711 cites W2050368996 @default.
- W4226257711 cites W2055402151 @default.
- W4226257711 cites W2065477010 @default.
- W4226257711 cites W2099530756 @default.
- W4226257711 cites W2099725888 @default.
- W4226257711 cites W2119852861 @default.
- W4226257711 cites W2134607826 @default.
- W4226257711 cites W2135192471 @default.
- W4226257711 cites W2136549983 @default.
- W4226257711 cites W2139110945 @default.
- W4226257711 cites W2147038864 @default.
- W4226257711 cites W2148832193 @default.
- W4226257711 cites W2151116840 @default.
- W4226257711 cites W2156098321 @default.
- W4226257711 cites W2163351155 @default.
- W4226257711 cites W2165010366 @default.
- W4226257711 cites W2167571044 @default.
- W4226257711 cites W2168691181 @default.
- W4226257711 cites W2228221433 @default.
- W4226257711 cites W2239287815 @default.
- W4226257711 cites W2324520777 @default.
- W4226257711 cites W2400514548 @default.
- W4226257711 cites W2460851798 @default.
- W4226257711 cites W246286872 @default.
- W4226257711 cites W2464088142 @default.
- W4226257711 cites W2482427906 @default.
- W4226257711 cites W2494021322 @default.
- W4226257711 cites W2494947788 @default.
- W4226257711 cites W2507654187 @default.
- W4226257711 cites W2551964258 @default.
- W4226257711 cites W2567769356 @default.
- W4226257711 cites W2568026712 @default.
- W4226257711 cites W2568245161 @default.
- W4226257711 cites W2569067657 @default.
- W4226257711 cites W2569092380 @default.
- W4226257711 cites W2581592505 @default.
- W4226257711 cites W2581996620 @default.
- W4226257711 cites W2587099123 @default.
- W4226257711 cites W2588199724 @default.
- W4226257711 cites W2588911215 @default.
- W4226257711 cites W2589099669 @default.
- W4226257711 cites W2609444947 @default.
- W4226257711 cites W2610816290 @default.
- W4226257711 cites W2613260339 @default.
- W4226257711 cites W2623725180 @default.
- W4226257711 cites W2624310346 @default.
- W4226257711 cites W2624982360 @default.
- W4226257711 cites W2626444729 @default.
- W4226257711 cites W2734805455 @default.
- W4226257711 cites W2746282229 @default.
- W4226257711 cites W2748599797 @default.
- W4226257711 cites W2757654439 @default.
- W4226257711 cites W2758367023 @default.
- W4226257711 cites W2761198389 @default.
- W4226257711 cites W2761226474 @default.
- W4226257711 cites W2761341070 @default.
- W4226257711 cites W2763649431 @default.
- W4226257711 cites W2763765527 @default.
- W4226257711 cites W2764070276 @default.
- W4226257711 cites W2766602847 @default.
- W4226257711 cites W2767231667 @default.
- W4226257711 cites W2767471408 @default.
- W4226257711 cites W2767670915 @default.
- W4226257711 cites W2767967204 @default.
- W4226257711 cites W2768071425 @default.
- W4226257711 cites W2769618607 @default.
- W4226257711 cites W2770722474 @default.
- W4226257711 cites W2784012638 @default.
- W4226257711 cites W2785515282 @default.
- W4226257711 cites W2793162088 @default.
- W4226257711 cites W2796631032 @default.
- W4226257711 cites W2797703810 @default.
- W4226257711 cites W2797959756 @default.
- W4226257711 cites W2801362524 @default.
- W4226257711 cites W2802418838 @default.
- W4226257711 cites W2803802743 @default.
- W4226257711 cites W2804475561 @default.
- W4226257711 cites W2804764624 @default.